Praetego is excited to present the latest data from its lead Amadorin candidate, PTG-630, at the BIO International Convention in San Diego, CA. CEO Pepper Landson will be speaking in Company Presentation Theater 2 on June 5th, 2024 at 11:30am PT. The presentation highlights reversal of cognitive decline in multiple animal models of Alzheimer’s disease (AD) and evidence of improving synaptic function in human derived brain cells from an AD patient. Data showing improvement on functional markers of AD pathology (amyloid, tau) will also be included.
PTG-630 is poised to start IND-enabling with the goal of starting clinical trials in 2025.
For more information and to save to your calendar, visit the BIO website.
